QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)

Rain Oncology (RAIN) Stock Forecast, Price & News

$1.29
+0.04 (+3.20%)
(As of 06/7/2023 ET)
Compare
Today's Range
$1.23
$1.30
50-Day Range
$1.09
$9.93
52-Week Range
$0.94
$14.48
Volume
1.66 million shs
Average Volume
906,389 shs
Market Capitalization
$46.90 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.00

Rain Oncology MarketRank™ Forecast

Analyst Rating
Hold
2.23 Rating Score
Upside/​Downside
1,217.8% Upside
$17.00 Price Target
Short Interest
Healthy
6.20% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.12mentions of Rain Oncology in the last 14 days
Based on 17 Articles This Week
Insider Trading
Selling Shares
$1.24 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.72) to ($1.08) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.85 out of 5 stars

Medical Sector

41st out of 981 stocks

Biotechnology Industry

1st out of 29 stocks


RAIN stock logo

About Rain Oncology (NASDAQ:RAIN) Stock

Rain Oncology Inc., a late-stage precision oncology company, engages in developing therapies that target oncogenic drivers to genetically select patients in the United States. The company's lead product candidate is milademetan, a small molecule oral inhibitor of MDM2-p53 complex that reactivates p53. The company was formerly known as Rain Therapeutics Inc. and changed its name to Rain Oncology Inc. in December 2022. Rain Oncology Inc. was incorporated in 2017 and is headquartered in Newark, California.

Receive RAIN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rain Oncology and its competitors with MarketBeat's FREE daily newsletter.

RAIN Stock News Headlines

Rain Oncology (NASDAQ:RAIN) Lowered to Neutral at Mizuho
[BREAKING] New "Living Software" to Revolutionize Warfare
This breakthrough will change "the way wars will be fought, and won, for years to come." - Chairman of the Joint Chief of Staff, General Mark Milley Get the name of the company supplying it to the U.S. Army here >>>
Mizuho Securities downgrades Rain Therapeutics (RAIN) to a Hold
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
Roth Mkm Lowers Rain Oncology (NASDAQ:RAIN) to Neutral
Rain Oncology (NASDAQ:RAIN) Cut to Neutral at Roth Capital
See More Headlines

RAIN Price History

RAIN Company Calendar

Last Earnings
5/11/2023
Today
6/07/2023
Next Earnings (Estimated)
8/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RAIN
Fax
N/A
Employees
63
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$17.00
High Stock Price Forecast
$24.00
Low Stock Price Forecast
$11.00
Forecasted Upside/Downside
+1,217.8%
Consensus Rating
Hold
Rating Score (0-4)
2.23
Research Coverage
13 Analysts

Profitability

Net Income
$-75,720,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.11 per share

Miscellaneous

Free Float
28,400,000
Market Cap
$46.90 million
Optionable
Not Optionable
Beta
0.01

Key Executives

  • Mr. Avanish Vellanki M.B.A. (Age 48)
    Co-Founder, CEO & Chairman
    Comp: $959.75k
  • Dr. Robert C. Doebele M.D. (Age 52)
    Ph.D., Co-Founder, Chairman of Scientific Advisory Board, Pres & Chief Scientific Officer
    Comp: $700.56k
  • Dr. Richard P. Bryce MBChB (Age 66)
    MFPM, MRCGP, Exec. VP & Chief Medical Officer
    Comp: $677.53k
  • Mr. Nelson D. Cabatuan (Age 45)
    Sr. VP of Fin. & Admin.
  • Ms. Theresa O'Connell M.S.
    Director of Corp. Devel. & Operations
  • Dr. Mehdi Paborji Ph.D. (Age 68)
    Sr. VP of Technical Operations
  • Mr. Erik Atkisson (Age 51)
    Gen. Counsel & Chief Compliance Officer
  • Ms. Charmi Turner
    VP of People & Culture
  • Ms. Vijaya Tirunagaru Ph.D.
    Sr. VP & Head of Research
  • Mr. Lucio Tozzi (Age 59)
    Sr. VP of Clinical Operations













RAIN Stock - Frequently Asked Questions

Should I buy or sell Rain Oncology stock right now?

13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Rain Oncology in the last twelve months. There are currently 10 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" RAIN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RAIN, but not buy additional shares or sell existing shares.
View RAIN analyst ratings
or view top-rated stocks.

What is Rain Oncology's stock price forecast for 2023?

13 brokers have issued 12-month price objectives for Rain Oncology's shares. Their RAIN share price forecasts range from $11.00 to $24.00. On average, they predict the company's stock price to reach $17.00 in the next twelve months. This suggests a possible upside of 1,217.8% from the stock's current price.
View analysts price targets for RAIN
or view top-rated stocks among Wall Street analysts.

How have RAIN shares performed in 2023?

Rain Oncology's stock was trading at $8.00 at the beginning of 2023. Since then, RAIN stock has decreased by 83.9% and is now trading at $1.29.
View the best growth stocks for 2023 here
.

When is Rain Oncology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our RAIN earnings forecast
.

How were Rain Oncology's earnings last quarter?

Rain Oncology Inc. (NASDAQ:RAIN) issued its quarterly earnings results on Thursday, May, 11th. The company reported ($0.56) EPS for the quarter, topping the consensus estimate of ($0.57) by $0.01.

What ETF holds Rain Oncology's stock ?

Horizon Kinetics Medical ETF holds 25,000 shares of RAIN stock, representing 0.97% of its portfolio.

When did Rain Oncology IPO?

(RAIN) raised $126 million in an initial public offering on Friday, April 23rd 2021. The company issued 7,400,000 shares at $16.00-$18.00 per share. Goldman Sachs, Citigroup, Piper Sandler and Guggenheim Securities served as the underwriters for the IPO.

What is Rain Oncology's stock symbol?

Rain Oncology trades on the NASDAQ under the ticker symbol "RAIN."

Who are Rain Oncology's major shareholders?

Rain Oncology's stock is owned by a number of institutional and retail investors. Top institutional investors include Perceptive Advisors LLC (4.53%), GMT Capital Corp (2.27%), Sectoral Asset Management Inc. (1.33%), FMR LLC (0.96%), Ghost Tree Capital LLC (0.69%) and Alyeska Investment Group L.P. (0.55%). Insiders that own company stock include Aaron I Davis, Boxer Capital, Llc, Bvf Partners L P/Il, Cormorant Asset Management, Lp, Franklin M Berger, Kevin C Tang, Perceptive Advisors Llc and Value Fund L P Biotechnology.
View institutional ownership trends
.

How do I buy shares of Rain Oncology?

Shares of RAIN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Rain Oncology's stock price today?

One share of RAIN stock can currently be purchased for approximately $1.29.

How much money does Rain Oncology make?

Rain Oncology (NASDAQ:RAIN) has a market capitalization of $46.90 million. The company earns $-75,720,000.00 in net income (profit) each year or ($2.60) on an earnings per share basis.

How can I contact Rain Oncology?

The official website for the company is www.rainthera.com. The company can be reached via phone at 510-953-5559 or via email at bob@lifesciadvisors.com.

This page (NASDAQ:RAIN) was last updated on 6/7/2023 by MarketBeat.com Staff

My Account -